Co-Founder Jared Stanley Resigns from Board to Lead Affiliated Biotech DeFloria
Summary
Charlotte's Web co-founder Jared Stanley has resigned from the Board of Directors to focus on his role as CEO of DeFloria, a clinical-stage pharmaceutical company co-founded by Charlotte's Web, which remains a shareholder.
Key Events
-
Co-Founder Resigns from Board
Jared Stanley, a co-founder of Charlotte's Web, resigned from the Board of Directors effective June 3, 2026.
-
Strategic Focus on DeFloria
Mr. Stanley will dedicate his full attention to his role as Chief Executive Officer of DeFloria, Inc., a clinical-stage botanical pharmaceutical company co-founded by Charlotte's Web.
-
Continued Affiliation and Advisory Role
Charlotte's Web remains a co-founder and shareholder in DeFloria, and Mr. Stanley will continue to support and advise Charlotte's Web where their work intersects.
-
No Disagreements Reported
The company explicitly stated that Mr. Stanley's decision does not relate to any disagreements with management or the board.
Analysis
This board transition is a strategic move, not a sign of disagreement, as co-founder Jared Stanley shifts his focus to leading DeFloria, a botanical pharmaceutical company in which Charlotte's Web holds a significant stake. His continued advisory role and Charlotte's Web's ownership in DeFloria suggest a coordinated effort to advance the clinical-stage drug program, potentially benefiting Charlotte's Web shareholders through its investment in the affiliated venture.
At the time of this filing, CWBHF was trading at $0.43 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $69.3M. The 52-week trading range was $0.08 to $0.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.